The aim of this study was to retrospectively evaluate the cost-effectiveness of three different TKIs (afatinib, erlotinib, and gefitinib) in patients with EGFR-mutated NSCLC from a single tertiary-care medical center located at a developing country. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.